Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × Aflatoxin Poisoning × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1143 Carcinoma, Non-Small-Cell Lung 812 Prostatic Neoplasms 662 Neoplasms 549 Lymphoma 483 Multiple Myeloma 481 Lung Neoplasms 475 Colorectal Neoplasms 475 Leukemia 436 Neoplasm Metastasis 421 Leukemia, Myeloid, Acute 414 Melanoma 386 Lymphoma, Non-Hodgkin 370 Ovarian Neoplasms 364 Leukemia, Lymphocytic, Chronic, B-Cell 342 Pancreatic Neoplasms 334 Recurrence 303 Precursor Cell Lymphoblastic Leukemia-Lymphoma 284 Head and Neck Neoplasms 268 Glioblastoma 267 Lymphoma, Large B-Cell, Diffuse 260 Brain Neoplasms 260 Stomach Neoplasms 258 Myelodysplastic Syndromes 255 Lymphoma, Follicular 249 Carcinoma, Renal Cell 237 Hodgkin Disease 233 Carcinoma, Hepatocellular 232 Rectal Neoplasms 230 Sarcoma 226

Interventions

sodium calcium aluminosilicate, hydrated 1 Calcium Carbonate 1 ACCS100 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01677195 2016-04-19

RDMEACCS100

Texas Enterosorbents Incorporated

Phase 2 Completed

234 enrolled 7 charts

Aflatoxin Poisoning, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡